Event Highlight: Upcoming Lymphoma Expert Forum
Advancing Lymphoma Treatment Together
Oncology Meeting Innovations (OMI) is hosting a Non-Hodgkin and Hodgkin Lymphoma Expert Forum on July 14th and 15th at the Hilton Anatole in Dallas, Texas. This program provides a forum for debate about the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of non-Hodgkin and Hodgkin lymphoma.
There will be a focus on the integration of novel therapies, such as checkpoint inhibitors, CAR-T therapy, and ADCs, into the current treatment paradigm. The meeting will also explore the management of toxicities, assessment of response and progression, and the influence of microenvironment on resistance and survival. The Expert Forum assembles a distinguished group of preclinical and translational experts for an open discussion on new data that will influence our knowledge of lymphoma over the coming years.
The Chairs for the Lymphoma Expert Forum are Brad S. Kahl, MD, John Pagel, MD, PhD, and Andrew D. Zelenetz, MD, PhD.
John M. Pagel, MD, PhD
John Pagel is the Chief of Hematologic Malignancies and Director of Stem Cell Transplantation at Fred Hutchinson Cancer Research Center in Seattle, WA. Dr. Pagel graduated Magna Cum Laude from Boston University School of Medicine and received his PhD from UC Irvine in Microbiology and Molecular Genetics. His research interests include radioimmunotherapy and nonradioactive chemical partners to antibodies.
Andrew D. Zelenetz, MD, PhD
Andrew Zelenetz is the Medical Director, Quality Informatics at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Zelenetz is former Chief of Memorial Sloan Kettering's Lymphoma Service. He is working to improve the prognostic value of patients' pathology specimens using computer-aided image analysis and has published more than 100 papers on lymphoma research in journals like Blood, Journal of Clinical Oncology, and Clinical Cancer Research.
Brad S. Kahl, MD
Brad S. Kahl is a Professor of Medicine at the Washington University School of Medicine in St. Louis, MO. Dr. Kahl studied medicine at Tufts University School of Medicine in Boston, MA and previously served as Director, Lymphoma Service at UW Health. He has clinical interests in lymphoma and CLL, as well as research interests in clinical trials and novel therapeutics. Dr. Kahl sits as chair for several national and international lymphoma committees.